Relationships between clinicopathological features and cerebrospinal fluid biomarkers in Japanese patients with genetic prion diseases

• Published in: PloS one 2013-03, Vol.8 (3), p.e60003
• Main Authors: Higuma, Maya, Sanjo, Nobuo, Satoh, Katsuya, Shiga, Yusei, Sakai, Kenji, Nozaki, Ichiro, Hamaguchi, Tsuyoshi, Nakamura, Yosikazu, Kitamoto, Tetsuyuki, Shirabe, Susumu, Murayama, Shigeo, Yamada, Masahito, Tateishi, Jun, Mizusawa, Hidehiro
• Format: Article
• Language: English
• Subjects: 14-3-3 protein; 14-3-3 Proteins - cerebrospinal fluid; 14-3-3 Proteins - genetics; Adult; Aged; Aging; Asian People; Autopsies; Biology; Biomarkers; Biomarkers - cerebrospinal fluid; Brain; Cerebrospinal fluid; Creutzfeldt-Jakob disease; Dementia; Family medical history; Female; Genotype; Genotype & phenotype; Genotypes; Humans; Immunoreactivity; Laboratories; Linear Models; Male; Medicine; Metabolism; Middle Aged; Mutation; Neurobiology; Neurology; Neuropathology; Neurosciences; NMR; Nuclear magnetic resonance; Patients; Prion Diseases - cerebrospinal fluid; Prion Diseases - genetics; Prion Diseases - pathology; Prion protein; Prion Proteins; Prions - cerebrospinal fluid; Prions - genetics; Proteins; Science; Surveillance; Tau protein; University graduates; Veterinary Science
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0060003

A national system for surveillance of prion diseases (PrDs) was established in Japan in April 1999. Here, we analyzed the relationships among prion protein gene (PRNP) mutations and the clinical features, cerebrospinal fluid (CSF) markers, and pathological characteristics of the major genotypes of genetic PrDs (gPrDs). We retrospectively analyzed age at onset and disease duration; the concentrations and incidences of 14-3-3 protein, tau protein, and abnormal prion protein (PrP(Sc)) in the CSF of 309 gPrD patients with P102L, P105L, E200K, V180I, or M232R mutations; and brain pathology in 32 autopsied patients. Three clinical phenotypes were seen: rapidly progressive Creutzfeldt-Jakob disease (CJD), which included 100% of E200K cases, 70% of M232R, and 21% of P102L; slowly progressive CJD, which included 100% of V180I and 30% of M232R; and Gerstmann-Sträussler-Scheinker disease, which included 100% of P105L and 79% of P102L. PrP(Sc) was detected in the CSF of more than 80% of patients with E200K, M232R, or P102L mutations but in only 39% of patients with V180I. V180I was accompanied by weak PrP immunoreactivity in the brain. Patients negative for PrP(Sc) in the CSF were older at disease onset than positive patients. Patients with mutations associated with high 14-3-3 protein levels in the CSF typically had synaptic deposition of PrP in the brain and a rapid course of disease. The presence of small PrP protein fragments in brain homogenates was not correlated with other clinicopathological features. Positivity for PrP(Sc) in the CSF may reflect the pathological process before or at disease onset, or abnormality in the secretion or metabolism of PrP(Sc). The amount of 14-3-3 protein in the CSF likely indicates the severity of the pathological process and accompanying neuronal damage. These characteristic features of the CSF in cases of gPrD will likely facilitate accurate diagnosis and clinicopathological study of the various disease subtypes.